Lupin receives US FDA approval for arthritis drug

The US Food and Drugs Administration (US FDA) has granted final approval for Lupin Limited’s Celecoxib capsules (50 mg), a generic version of GD Searle LLC’s (a subsidiary of Pfizer Inc) Celebrex capsules 50 mg. The Mumbai-based pharma major has also received tentative approvals for its Celecoxib capsules 100 mg, 200 mg and 400 mg strengths from the FDA.
 
Lupin's Celecoxib capsules are indicated for osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis in patients 2 years and older; ankylosing spondylitis, and acute pain.
 
According to IMS MAT June, 2014 data, Celebrex capsules had annual US sales of $ 2.44 billion.